Extended Data Fig. 4: Neither HLA-I heterozygosity nor HLA-I evolutionary divergence is associated with prognosis in TCGA melanoma patients.
From: Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy
a, Full heterozygosity at HLA-I (red) is not associated with prognosis in TCGA melanoma patients; P = 0.14, two-sided log-rank test. b, High patient mean HED (red) is not associated with prognosis in TCGA melanoma patients; P = 0.80, two-sided log-rank test. c, High mean HED (red) is not associated with prognosis in TCGA melanoma patients fully heterozygous at HLA-I; P = 0.54; two-sided log-rank test.
